Impact of SGLT2 on Glucosuria in HNF1A-MODY
Launched by STENO DIABETES CENTER COPENHAGEN · Jun 9, 2022
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
Participants: Patients with HNF1A-MODY (n=12) and patients with T2D (n=12)
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • HNF1A-MODY verified by genetic testing (only patients with HNF1A-MODY)
- • Type 2 diabetes diagnosis according to World Health Organization (only patients with type 2 diabetes)
- • Treatment with diet and/or a glucose-lowering drug (only patients with HNF1A-MODY)
- • Normal haemoglobin (males 8.3-10.5 mmol/l, females 7.3-9.5 mmol/l)
- • Informed consent
- Exclusion Criteria:
- • Nephropathy (estimated GFR \<60 ml/min/1.73m2 and/or albuminuria)
- • Known significant liver disease and/or plasma alanine aminotransferase (ALT) and/or plasma aspartate aminotransferase (AST) above 2 × normal values)
- • Pregnancy or breastfeeding
- • Treatment with SGLT2 inhibitor
- • Fasting plasma glucose \> 10 mmol/l
- • Family history of HNF1A-MODY (only patients with type 2 diabetes)
About Steno Diabetes Center Copenhagen
Steno Diabetes Center Copenhagen is a leading clinical research facility dedicated to advancing the understanding and treatment of diabetes and its complications. As a prominent sponsor of clinical trials, the center focuses on innovative research that bridges clinical practice and scientific inquiry, fostering collaborations with healthcare professionals, researchers, and patients. Committed to improving patient outcomes, Steno Diabetes Center Copenhagen emphasizes evidence-based approaches and cutting-edge methodologies to enhance diabetes management and care, ultimately contributing to the global fight against this chronic disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Herlev, , Denmark
Patients applied
Trial Officials
Tina Vilsbøll
Principal Investigator
Steno Diabetes Center Copenhagen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials